Tirzepatide Shows Cost-Effectiveness for Heart Failure with Obesity Management

Heart Failure with Preserved Ejection Fraction (HFpEF) is a debilitating condition often co-occurring with obesity, significantly increasing morbidity and healthcare costs. While Tirzepatide has demonstrated efficacy in weight loss and cardiovascular risk reduction, its economic value in the specific context of HFpEF patients with obesity has not been thoroughly evaluated.

The analysis revealed that adding Tirzepatide to standard care resulted in an incremental gain of 0.85 QALYs per patient over 10 years compared to standard care alone. This benefit came at an incremental cost of $65,000 per patient, primarily driven by drug acquisition. Consequently, the Incremental Cost-Effectiveness Ratio (ICER) for Tirzepatide was calculated to be approximately $76,470 per QALY gained. > The study concluded that Tirzepatide was cost-effective for managing HFpEF and obesity, as its ICER of $76,470/QALY fell below the commonly accepted willingness-to-pay threshold of $100,000 to $150,000 per QALY in the United States. Sensitivity analyses confirmed the robustness of these findings, showing that Tirzepatide had a 75% probability of being cost-effective at a $100,000/QALY threshold, even under varying assumptions for drug price and clinical efficacy.